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Propionibacterium acnes isomerase. 
We have previously demonstrated that oral administration of a metabolically 
active Bifidobacterium breve strain, with ability to form cis-9, trans-11 conjugated 
linoleic acid (CLA), resulted in modulation of the fatty acid composition of the 
host, including significantly elevated concentrations of c9, t11 CLA and omega-3 
(n-3) fatty acids in liver and adipose tissue. In this study, we investigated whether 
a recombinant lactobacillus expressing CLA isomerase from Propionibacterium 
acnes could influence the fatty acid composition of different tissues in a mouse 
model. Linoleic-acid-supplemented diets (2%, w/w) were fed in combination with 
either a recombinant t10, c12 CLA-producing Lactobacillus paracasei NFBC 338 
(Lb338), or an isogenic (vector-containing) control strain, to BALB/c mice for 8 
weeks. A third group of mice received linoleic acid alone (2%, w/w). Tissue fatty 
acid composition was assessed by GLC at the end of the trial. Ingestion of the 
strain expressing CLA isomerase was associated with a 4-fold increase (P<0.001) 
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in t10, c12 CLA in adipose tissues of the mice when compared with mice that 
received the isogenic non-CLA-producing strain. The livers of the mice that 
received the recombinant CLA-producing Lb338 also contained a 2.5-fold (albeit 
not significantly) higher concentration of t10, c12 CLA, compared to the control 
group. These data demonstrate that a single gene (encoding CLA isomerase) 
expressed in an intestinal microbe can influence the fatty acid composition of 
host fat. 
Introduction 
Evidence is emerging to support the concept that the enteric microbiota can exert profound effects 
on human health and disease, involving complex host–bacteria interactions that are as yet poorly 
understood. The gut microbiota is important to the host with regard to metabolic functions, 
providing nutrients and conferring an ability to resist bacterial infections (Marchesi & Shanahan, 
2007; Wilks, 2007), as well as playing a dominant role in the education of the intestinal mucosal 
immune responses. Furthermore, the enteric microbiota has been shown to exert effects on disease 
processes outside the gut, including an impact on obesity and non-alcoholic fatty liver disease 
(Dumas et al., 2006; Marchesi & Shanahan, 2007). 
Conjugated linoleic acid (CLA) is a beneficial bacterial metabolite formed via microbial 
isomerization of linoleic acid. CLA is a collective term describing different isomers of linoleic acid 
with conjugated double bonds, the cis-9, trans-11 (c9, t11) CLA isomer being the most abundant 
form and the t10, c12 CLA isomer accounting for ~1% of total milk fat CLA (Jensen, 2002). It has 
been reported that t10, c12 CLA is the most potent isomer in terms of potential to prevent cell 
proliferation and induce apoptosis in cancer cells (Cho et al., 2005, 2006; Kim et al., 2002a; Lee et 
al., 2006b; Ochoa et al., 2004). t10, c12 CLA is also associated with decreased body fat and 
increased lean body mass in various animal species, such as mice (Park et al., 1997), chickens 
(Cherian et al., 2005), rats (Yamasaki et al., 2003), hamsters (Navarro et al., 2006), pigs 
(Ostrowska et al., 1999) and, to some extent, humans (Blankson et al., 2000; Mougios et al., 2001; 
Risérus et al., 2001; Smedman & Vessby, 2001; Thom et al., 2001). Commensal Bifidobacterium 
and Lactobacillus species from the mammalian gastrointestinal tract have been shown to produce 
CLA in vitro (Barrett et al., 2007; Coakley et al., 2003; Rosberg-Cody et al., 2004). The majority of 
these studies have demonstrated production of c9, t11 CLA from linoleic acid, while only a few 
bacterial species have been reported to produce t10, c12 CLA, i.e. Propionibacterium acnes isolated 
from mouse caecum (Verhulst et al., 1987), the rumen bacterium Megasphaera elsdenii (Kim et al., 
2002b) and the human-derived Lactobacillus rhamnosus PL60 and Lactobacillus plantarum PL62 
(Lee et al., 2006a; Lee et al., 2007). However, only a few studies have established CLA production 
in vivo following ingestion of a CLA-producing bacterium. For example, the in vivo production of 
t10, c12 CLA was reported by Lactobacillus rhamnosus PL60 and Lactobacillus plantarum PL62 
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(Lee et al., 2006a, 2007), and we recently demonstrated that feeding different animal species a c9, 
t11 CLA-producing Bifidobacterium strain of human origin (Bifidobacterium breve NCIMB 
702258), in combination with linoleic acid as substrate, resulted in modulation of the fatty acid 
composition of the host, including significantly elevated concentrations of c9, t11 CLA in the liver 
(Wall et al., 2009). 
The enzyme Propionibacterium acnes isomerase (PAI) is responsible for conversion of linoleic acid 
to the t10, c12 CLA isomer and has previously been expressed in bacteria, yeast and tobacco seeds 
(Hornung et al., 2005). We have successfully cloned and overexpressed PAI in Lactococcus lactis, 
resulting in conversion rates of >50% of linoleic acid to t10, c12 CLA (Rosberg-Cody et al., 2007). 
Moreover, when the microbially derived t10, c12 CLA was incubated with SW480 colon cancer 
cells for 5 days, cell viability was decreased by 92% (Rosberg-Cody et al., 2007). The objective of 
this study was to investigate whether a recombinant Lactobacillus paracasei NFBC 338 (Lb338), 
expressing the gene encoding PAI, would result in elevated tissue concentrations of t10, c12 CLA 
in vivo. 
Methods 
Cultures and media. 
The probiotic strain Lactobacillus paracasei NFBC 338 (Lb338) was previously isolated from the 
human gastrointestinal tract, and obtained from University College Cork, Ireland, under a restricted 
materials transfer agreement. Lb338 was routinely cultured overnight (~17 h) in de Man–Rogosa–
Sharpe (MRS) broth (Oxoid) and incubated at 37 °C under anaerobic conditions using anaerobic 
jars containing Anaerocult A gas packs (Merck). Lb338 harbouring the vector pMSP3535 was 
routinely cultured with erythromycin (10 µg ml−1; Sigma) as a selective marker. 
DNA manipulation. 
The 1278 bp coPAI gene (codon-optimized Propionibacterium acnes isomerase in a plant vector; 
BASF), encoding the t10, c12 conjugated linoleic acid isomerase from P. acnes (Hornung et al., 
2005) was amplified and cloned into the nisin-inducible lactococcal plasmid pNZ8048 (containing 
the PnisA promoter) as described previously (Rosberg-Cody et al., 2007). The coPAI gene was 
excised from pNZ8048-coPAI using PstI and XbaI restriction enzymes and ligated into the same 
sites of the Lactobacillus nisin-inducible plasmid pMSP3535 (Bryan et al., 2000), as described by 
the supplier (New England Biolabs), resulting in the construct pEcoPAIL (Fig. 1). The recombinant 
plasmid was double-digested with the same enzymes to verify the correct clone and subsequently 
electroporated into Lb338. Electrocompetent Lb338 cells were prepared using 3.5× SMEB (1 M 
sucrose, 3.5 mM MgCl2), as described by Luchansky et al. (1988). Sequence analysis was 
performed using DNASTAR software. The Qiagen Plasmid Mini kit was used to isolate plasmid DNA 
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from Lb338 with one minor modification: 40 mg lysozyme ml−1 was added to buffer P1 and 
incubated for 2 h at 37 °C. PCR products were purified using a Qiaquick PCR Purification kit 
(Qiagen). 
In vitro conversion of t10, c12 CLA by recombinant lactobacilli. 
The recombinant Lb338 was assessed for its ability to convert free linoleic acid (0.5 mg ml−1, 
Sigma) to t10, c12 CLA as follows. A 1% (v/v) inoculum of an overnight culture was transferred to 
10 ml broth and incubated until the OD600 reached ~0.5. The culture was then induced with 50 ng 
nisin ml−1 (Sigma) (sterile-filtered through a 45 µm filter) and linoleic acid was added prior to 
further incubation for 48 h, after which the culture was centrifuged (4345 g for 15 min). Fatty acids 
were extracted from the supernatant and cell pellets, followed by methylation and analysis by GLC 
as previously described (Coakley et al., 2003). 
Preparation and administration of the probiotic cultures. 
Lb338 was initially grown in MRS broth, as described above. The culture was centrifuged (7000 g 
for 15 min at 4 °C; Sorvall RC5B Plus, SLA-3000 rotor), and the pellet was washed twice in PBS 
(Sigma) and resuspended at 1×1010 cells ml−1 in 15% (w/v) trehalose (Sigma) in distilled H2O. One-
millilitre aliquots were dispensed into 2 ml vials and freeze-dried using a 24 h programme (freeze 
temperature −40 °C, condenser set point −60, vacuum set point 600 mTorr). Each mouse that 
received live probiotic culture was administered approximately 1×109 live micro-organisms per day. 
This was achieved by resuspending appropriate quantities of freeze-dried powder in the water that 
the mice consumed ad libitum. 
Animals and dietary treatments. 
Male BALB/c mice were purchased from Harlan at 8 weeks of age and were fed ad libitum with 
standard nonpurified CRM(P) diet (Special Diets Services) with free access to water at all times. 
The standard diet had the following nutrient composition: nitrogen-free extract (57.39%), crude 
protein (18.35%), moisture (10%), ash (6.27%), crude fibre (4.23%) and crude oil (3.36%), which 
consisted of saturated fatty acids [lauric acid (C12:0, 0.03%), myristic acid (C14:0, 0.14%), 
palmitic acid (C16:0, 0.33%) and stearic acid (C18:0, 0.06%)], monounsaturated fatty acids 
[myristoleic acid (C14:1, 0.02%), palmitoleic acid (C16:1, 10%) and oleic acid (C18:1, 0.87%)] and 
polyunsaturated fatty acids [linoleic acid (C18:2n-6, 0.96%), linolenic acid (C18:3n-3, 0.11%) and 
arachidonic acid (C20:4n-6, 0.11%)]. t10, c12 CLA was not detected in the diet. For linoleic acid 
treatment (added as trilinolein, with linoleic acid being the only fatty acid; Larodan Fine 
Chemicals), a powdered diet [milled standard non-purified CRM(P) pellets] blended with the fatty 
acid was administered to each animal daily to yield approximately 180 mg linoleic acid per day. 
The mice would consume this diet within a few minutes. Mice were individually caged and exposed 
to a 12 h light/dark cycle, maintained at a constant temperature of 25 °C. 
Page 5 of 14 
All laboratory animal experiments were performed according to the guidelines for the care and use 
of laboratory animals approved by the Department of Health and Children of the Irish Government. 
One week after arrival, mice were divided into three groups for different dietary treatments. Group 
A (n=8) received a linoleic-acid-supplemented diet (2%, w/w, Larodan Fine Chemicals) and 
approximately 1×109 live t10, c12 CLA-producing Lb338 (carrying the plasmid construct 
pEcoPAIL) per day. The probiotic culture was administered by resuspending appropriate quantities 
of freeze-dried powder in the water that the mice consumed. Group B (n=8) received the linoleic-
acid-supplemented diet (2%, w/w) in combination with approximately 1×109 live non-CLA-
producing Lb338 (carrying the empty plasmid pMSP3535) per day. Group C (n=5) received a 
linoleic-acid-supplemented diet (2%, w/w) and placebo freeze-dried powder (15%, w/v, trehalose in 
distilled H2O). After 8 weeks on the experimental diets, the mice were sacrificed by cervical 
dislocation, and tissues were removed, blotted dry on filter paper, weighed and frozen in liquid 
nitrogen. All samples were stored at −80 °C until processed. 
Microbial analysis. 
Microbial analysis of faecal samples collected from all groups every 2 weeks involved enumeration 
of Lb338 by pour-plating serial dilutions onto MRS agar supplemented with erythromycin (10 µg 
ml−1, Sigma). Agar plates were incubated anaerobically for 72 h at 37 °C. Anaerobic environments 
were created using CO2-generating kits (Anaerocult A) in sealed gas jars. 
Lipid extraction and fatty acid analysis. 
Lipids were extracted with chloroform/methanol (2:1, v/v) according to the method of Folch et al. 
(1957). Fatty acid methyl esters (FAMEs) were prepared using first 10 ml 0.5 M NaOH in methanol 
for 10 min at 90 °C followed by 10 ml 14% BF3 in methanol (Sigma) for 10 min at 90 °C (Park & 
Goins, 1994). FAMEs were recovered with hexane. Prior to GLC analysis, samples were dried over 
0.5 g anhydrous sodium sulphate for 1 h and stored at −20 °C. FAMEs were separated by GLC 
(Varian 3400 instrument fitted with a flame-ionization detector) using a Chrompack CP Sil 88 
column (100 m×0.25 mm i.d., 0.20 µm film thickness) and helium as carrier gas. The column oven 
temperature was initially held at 80 °C for 8 min, and then increased at 8.5 °C min−1 to a final 
temperature of 200 °C. The injection volume was 0.6 µl with automatic sample injection on a SPI 
1093 splitless on-column temperature programmable injector. Data were recorded and analysed on 
a Minichrom PC system (VG Data Systems). Peaks were identified with reference to retention times 
of fatty acids in a standard mixture. The percentage of individual fatty acids was calculated 
according to the peak area relative to the total area (total fatty acids were set at 100%). Results are 
shown as mean±SEM g per 100 g FAMEs. 
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Statistical analysis. 
Data are presented as means±SEM per group of mice. Data were analysed using analysis of variance 
(ANOVA) followed by Tukey’s post-hoc test using GraphPad InStat version 3.05. 
Results 
Microbial production of t10, c12 CLA by recombinant L. paracasei NFBC 338 (Lb338) 
Lb338 harbouring the nisin-inducible Lactobacillus plasmid containing the coPAI gene, pEcoPAIL 
(Fig. 1), converted approximately 30% of linoleic acid to t10, c12 CLA, following induction at 
OD600 0.5 with 50 ng nisin ml−1 and incubation for 48 h in the presence of the free fatty acid 
substrate (0.5 mg ml−1). However, t10, c12 CLA production by uninduced cells of Lb338 
pEcoPAIL was similar to that obtained with nisin-induced cells (24.4±0.4% and 28.9±0.5% 
conversion of substrate to product, respectively). Lb338 transformed with the empty vector 
pMSP3535 did not convert any of the added linoleic acid to t10, c12 CLA. 
Survival and gastric transit of administered lactobacilli and confirmation of ability to 
produce t10, c12 CLA following gastric transit 
Quantification of the numbers of bacteria of the recombinant CLA-producing Lb338 (group A) and 
the non-CLA-producing isogenic control Lb338 (group B) monitored in the faeces of mice 
confirmed gastrointestinal transit and survival of the administered strains. Stool recovery of the 
recombinant CLA-producing Lb338 and the non-CLA-producing isogenic control Lb338 was 
approximately 1×107 c.f.u. (g faeces)−1 at week 2, which increased to approximately 1×108 c.f.u. (g 
faeces)−1 at week 4 and remained at ~1×108 c.f.u. (g faeces)−1 throughout the rest of the trial. 
Recovered Lactobacillus isolates (from groups A and B) were inoculated into MRS broth 
containing linoleic acid (0.5 mg ml−1), which confirmed that the recovered Lb338 from group A, 
but not from group B, retained the ability to convert linoleic acid to t10, c12 CLA following 
passage through the gastrointestinal tract (data not shown). 
Oral administration of the recombinant CLA-producing Lb338 (group A) and the non-CLA-
producing isogenic control Lb338 (group B) did not significantly influence body weight gain 
throughout the feeding trial (Fig. 2). In addition, liver weights were not significantly different 
between the groups (data not shown). 
In vivo production of t10, c12 CLA by recombinant lactobacilli in mice 
Following 8 weeks of dietary treatment, it was demonstrated that t10, c12 CLA was produced by 
the recombinant Lb338 in the gastrointestinal tract of mice. The mean t10, c12 CLA content of the 
adipose tissue was 4-fold higher in the mice that received the recombinant CLA-producing Lb338 
in combination with linoleic acid (group A) compared with the isogenic control (group B) 
(P<0.001, Fig. 3). This higher concentration of t10, c12 CLA in Group A coincided with an 
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approximately 20% lower concentration of linoleic acid in the adipose tissue (although the 
difference was not statistically significant) in comparison to group B (Table 2). Oral administration 
of the recombinant CLA-producing Lb338 (group A) also resulted in a 2.5-fold higher 
concentration of t10, c12 CLA in the livers compared with group B (non-CLA-producing Lb338), 
although the difference was not statistically significant (Fig. 3). 
Dietary supplementation with probiotic Lb338 changes host tissue fatty acid 
composition 
Changes in tissue fatty acid composition caused by dietary supplementation with the probiotic 
Lb338 were investigated by comparing the groups of mice that received Lb338 (groups A and B) 
with the group that received linoleic acid alone (group C). 
The mice that received Lb338 (groups A and B) had a significantly lower concentration of oleic 
acid in the spleen (P<0.01) and a numerically lower concentration of oleic acid in the adipose tissue 
compared to mice that received linoleic acid alone (Fig. 4). Furthermore, administration of Lb338 
(groups A and B) resulted in lower concentrations of arachidonic acid in the liver (17% and 19%, 
lower, respectively) compared to mice that received linoleic acid alone (group C), although the 
differences were not statistically significant (Table 1). 
Discussion 
This study demonstrates that t10, c12 CLA production occurred in vivo when a recombinant 
Lactobacillus strain harbouring the gene encoding t10, c12 CLA isomerase was administered to 
mice. As a direct consequence of this, the t10, c12 CLA content of adipose tissue was elevated 
fourfold in animals that received the recombinant t10, c12 CLA-producing Lb338 in combination 
with linoleic acid compared to mice that received the isogenic control strain. t10, c12 CLA has been 
shown to be beneficial to host health (Kim et al., 2002a; Ochoa et al., 2004; Yamasaki et al., 2003) 
and has been demonstrated to alter body composition by reducing the fat content and increasing the 
lean body mass in animal studies, and also in some human studies (Blankson et al., 2000; Smedman 
& Vessby, 2001; Thom et al., 2001). It was reported by Lee et al. (2006a) that t10, c12 CLA was 
produced in vivo when the human-originated bacterium L. rhamnosus PL60 was fed to diet-induced 
obese mice. The relatively low amount of t10, c12 CLA produced by this strain (1.9 µg ml−1 was 
detected in the sera) was enough to produce an anti-obesity effect. Moreover, liver steatosis, a well-
known side effect of t10, c12 CLA, was not observed following L. rhamnosus PL60 treatment in 
this study (Lee et al., 2006a). Thus, the lower dose of CLA produced by a probiotic strain may be a 
reliable solution to control the adverse effects caused by dietary t10, c12 CLA, i.e. liver steatosis. In 
addition, we have previously shown that the microbially derived t10, c12 CLA, at a concentration of 
20 µg ml−1, has the ability to kill 92% of human SW480 colon cancer cells when co-incubated with 
these cells for 5 days (Rosberg-Cody et al., 2007). In contrast to dietary CLA, which is primarily 
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absorbed from the small intestine, using a t10, c12 CLA-producing strain would result in the 
provision of t10, c12 CLA directly and continuously to the large intestinal lumen, where this fatty 
acid would exhibit anti-inflammatory and anti-proliferative effects on colonocytes (Bassaganya-
Riera et al., 2004; Kemp et al., 2003), thereby contributing to colonic mucosal homeostasis. 
Although the t10, c12 CLA content was significantly higher in the animals that received the t10, 
c12 CLA-producing recombinant strain, lower concentrations of t10, c12 CLA was also detected in 
animals that did not receive this strain. One possible explanation for this may be that the natural 
enteric microbiota of mice can produce some t10, c12 CLA, using linoleic acid as substrate. In this 
respect, it is worth noting that the origin of the PAI gene used in this study to transform Lb338 is 
Propionibacterium acnes, a strain that was originally isolated from mouse caecum (Verhulst et al., 
1987). 
Interestingly, administration of L. paracasei NFBC 338 (both the recombinant strain and the 
isogenic control) in combination with linoleic acid resulted in lower concentrations of arachidonic 
acid in the liver (17% and 19% lower, respectively) compared to mice that received linoleic acid 
alone. Since the eicosanoids derived from arachidonic acid, such as the 2-series prostaglandins and 
the 4-series leukotrienes, are in general regarded as being pro-inflammatory in nature (Bagga et al., 
2003), decreased amounts of arachidonic acid would be considered beneficial, especially in chronic 
inflammatory settings that are of high prevalence in Western societies such as inflammatory bowel 
disease, cardiovascular disease and obesity, which are characterized by an excessive production of 
arachidonic-acid-derived eicosanoids (Calder, 2001; James et al., 2000; Jupp et al., 2007; Wallace, 
2001). Administration of L. paracasei NFBC 338 also resulted in significantly lower concentrations 
of oleic acid in the spleen and adipose tissue compared to mice that received linoleic acid alone. 
Furthermore, our data indicate that it was not the t10, c12 CLA isomerase gene, but the 
administered probiotic lactobacilli that was responsible for the decreased oleic acid observed in 
probiotic-supplemented animals compared with unsupplemented controls. Previously, Kalavathy et 
al. (2006) reported that administration of a mixture of Lactobacillus to broiler chickens significantly 
reduced the concentrations of oleic acid in liver and muscle. A reduced concentration of oleic acid 
has also been observed in the liver of rats fed a mixture of probiotics (Fukushima et al., 1999). This 
lower concentration of oleic acid could possibly be due to a reduction in the synthesis of the fatty 
acid or a reduced absorption from the intestine. 
In conclusion, this is to our knowledge the first report to demonstrate that oral administration of a 
genetically modified t10, c12 CLA-producing strain (containing the single gene for t10, c12 CLA 
production) results in modulation of the fatty acid composition of the host, including significantly 
higher concentrations of t10, c12 CLA in adipose tissue, which is directly attributable to the 
presence of the t10, c12 CLA isomerase gene. 
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Table 1. Fatty acid composition (%) of livers from BALB/c mice 
Data are means (±SEM) (group A and group B, n=8; group C, n=5). Different superscript letters 
within a row indicate significant difference at P<0.05 based on ANOVA followed by Tukey’s post-
hoc test. 
Fatty acid* Fatty acid composition (g per 100 g FAMEs) 
 Group A 
(Lb338+linoleic 
acid) 
Group B (isogenic 
control 
strain+linoleic 
acid) 
Group C 
(linoleic acid) 
14:0 1.7 (0.26)b,c 0.55 (0.26)a 0.29 (0.03)a 
16:0 17.82 (0.80) 18.30 (0.42) 19.5 (0.58) 
16:1c9 0.8 (0.08) 0.8 (0.06) 0.67 (0.04) 
18:0 12.63 (1.07) 13.08 (0.82) 15.59 (0.35) 
18:1c9 5.96 (0.34) 6.93 (0.46) 5.97 (0.16) 
18:2n-6 30.89 (2.07) 31.40 (4.02) 28.38 (0.46) 
18:3n-3 1.02 (0.68) 0.38 (0.04) 0.3 (0.02) 
18:3n-6 0.69 (0.09) 0.68 (0.06) 0.51 (0.03) 
t10, c12 CLA 0.010 (0.003) 0.004 (0.001) 0.006 (0.003) 
18:4n-3 0.41 (0.03) 0.51 (0.06) 0.38 (0.02) 
20:3n-6 0.69 (0.09) 0.65 (0.04) 0.78 (0.03) 
20:4n-6 12.48 (1.05) 12.27 (0.82) 15.08 (0.41) 
20:5n-3 0.04 (0.003) 0.04 (0.003) 0.05 (0.004) 
22:5n-3 0.20 (0.007) 0.21 (0.01) 0.23 (0.004) 
22:6n-3 4.91 (0.20)c 5.17 (0.34) 6.17 (0.13)a 
*14:0, myristic acid; 16:0, palmitic acid; 16:1c9, palmitoleic acid; 18:0, stearic acid; 18:1c9, oleic acid; 18:2n-6, 
linoleic acid; 18:3n-3, linolenic acid; 18:3n-6, γ-linolenic acid; 18:4n-3, stearidonic acid; 20:3n-6, dihomo-γ-linolenic 
acid; 20:4n-6, arachidonic acid; 20:5n-3, eicosapentaenoic acid; 22:5n-3, docosapentaenoic acid; 22:6n-3 
docosahexaenoic acid. 
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Table 2. Fatty acid composition (%) of adipose tissue from BALB/c mice 
Data are means (±SEM) (group A and group B, n=8; group C, n=5). Different superscript numbers 
within a row indicate significant difference at P<0.05 based on ANOVA followed by Tukey’s post 
hoc test. ND, not detectable.  
Fatty acid* Fatty acid composition (g per 100 g FAMEs) 
 Group A 
(Lb338+linoleic 
acid) 
Group B (isogenic 
control 
strain+linoleic acid) 
Group C (linoleic 
acid) 
14:0 2.0 (0.2) 1.39 (0.2) 1.9 (0.31) 
16:0 23.04 (0.59) 21.73 (1.12) 22.42 (0.53) 
16:1c9 0.89 (0.54) 1.24 (0.38) 1.08 (0.34) 
18:0 16.43 (0.75) 13.43 (1.69) 14.76 (0.93) 
18:2n-6 22.4 (1.26) 26.88 (2.65) 25.1 (1.5) 
18:3n-3 0.13 (0.007) 0.13 (0.007) 0.15 (0.04) 
18:3n-6 0.23 (0.01) 0.21 (0.03) 0.26 (0.05) 
18:4n-3 0.07 (0.02)c 0.03 (0.007)b NDa 
20:3n-6 0.12 (0.01) 0.10 (0.01) 0.11 (0.01) 
20:4n-6 18.82 (0.92) 15.65 (2.69) 17.68 (1.28) 
20:5n-3 0.07 (0.001) 0.08 (0.007) 0.06 (0.004) 
22:5n-3 0.29 (0.01) 0.26 (0.04) 0.31 (0.03) 
22:6n-3 1.4 (0.06) 1.2 (0.2) 1.33 (0.13) 
*See Table 1 for full names of fatty acids. 
Fig. 1. Plasmid construct pEcoPAIL used to transform Lb. paracasei NFBC 338 (Lb 338). ‘coPAI’ 
denotes the codon-optimized P. acnes isomerase gene (t10, c12 CLA isomerase). 
Fig. 2. Percentage body weight gain of mice fed t10, c12 CLA-producing recombinant Lb338 in 
combination with linoleic acid (2%, w/w) (group A, n=8; ■), isogenic control strain in combination 
with linoleic acid (2%, w/w) (group B, n=8; ▲) and linoleic acid alone (2%, w/w) (group C, n=5; 
). Initial body weights: group A, 24.7±0.3 g; group B, 24.5±0.5 g; group C, 24.9±0.5 g. There 
were no significant differences between the groups. 
Fig. 3. t10, c12 CLA concentration of adipose tissue following 8 weeks supplementation. Group A: 
t10, c12 CLA-producing recombinant Lb338 in combination with linoleic acid (2%, w/w) (n=8). 
Group B: isogenic control strain in combination with linoleic acid (2%, w/w) (n=8). Group C: 
linoleic acid alone (2%, w/w) (n=5). Statistical significance was determined by ANOVA followed 
by Tukey’s post hoc test; ***P<0.001. 
Fig. 4. Oleic acid concentrations in murine spleen and adipose tissue. Group A: t10, c12 CLA 
producing recombinant Lb338 in combination with linoleic acid (2%, w/w) (n=8). Group B: 
isogenic control strain in combination with linoleic acid (2%, w/w) (n=8). Group C: linoleic acid 
alone (2%, w/w) (n=5). Statistical significance was determined by ANOVA followed by Tukey’s 
post hoc test; **P<0.01. 
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